Literature DB >> 3919125

The role of the fibrinolytic system in deep vein thrombosis.

B Wiman, B Ljungberg, J Chmielewska, G Urdén, M Blombäck, H Johnsson.   

Abstract

Some aspects of the function of the fibrinolytic system have been investigated in 37 patients with a recent incident of symptomatic and confirmed deep vein thrombosis and compared with findings in 20 healthy persons. New specific methods to measure tissue plasminogen activator (t-PA) activity and antigen before and after venous occlusion and the recently discovered fast inhibitor to t-PA were employed. Thirteen of the patients with deep vein thrombosis (35%) had t-PA activity less than 0.5 IU/ml after venous occlusion, whereas the lowest activity found among the healthy individuals was 0.56 IU/ml. The t-PA inhibitor level in the total patient group was 3.8 +/- 3.7 U/ml (range 0 to 15.0 U/ml; median 2.9 U/ml) as compared with 0.7 +/- 0.7 U/ml in the healthy (median 0.5, range 0 to 2.4 U/ml). In the 13 patients with low t-PA activity in postocclusion plasma samples the inhibitor level was 6.0 +/- 4.4 U/ml. Furthermore, in this group of patients a significantly lesser release of t-PA antigen (3.7 +/- 2.8 micrograms/L) was found as compared with that in the healthy individuals (9.5 +/- 6.0 micrograms/L). Thus, two months after their first incident of symptomatic deep vein thrombosis many of the patients (35%) were found to have decreased fibrinolytic activity. This is the result of highly increased plasma levels of a novel fast inhibitor toward t-PA in combination with a poor ability to release t-PA. Possibly the decreased fibrinolytic activity did play a role in the pathogenesis of deep vein thrombosis in these patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919125

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  16 in total

Review 1.  Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology.

Authors: 
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Authors:  D Ginsburg; R Zeheb; A Y Yang; U M Rafferty; P A Andreasen; L Nielsen; K Dano; R V Lebo; T D Gelehrter
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  Naturally occurring canine nephrotic syndrome is a potentially hypercoagulable state.

Authors:  A Rasedee; B F Feldman; R Washabau
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

Review 5.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

6.  Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.

Authors:  R Sawaya; P Glas-Greenwalt
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

7.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

8.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.

Authors:  T D Gelehrter; R Sznycer-Laszuk
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

9.  Tissue type plasminogen activator antigen and activity in sickle cell disease.

Authors:  R B Francis
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

10.  Changes in the fibrinolytic system associated with physical conditioning.

Authors:  J A De Paz; J Lasierra; J G Villa; E Viladés; M A Martín-Nuño; J González-Gallego
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.